• Erlotinib (NSC 718781) in EGFR Research

  2026-09-04

  Erlotinib provides a precise small-molecule probe for EGFR kinase activity, connecting phospho-signaling measurements with proliferation, apoptosis, and resistance studies. This workflow shows how to use it as an EGFR pathway comparator in SCUBE3-driven cancer models without mistaking downstream pathway suppression for direct SCUBE3 neutralization.

• Biotin-XX Tyramide Reagent: Reliable Cell-Surface Assays

  2026-09-03

  Biotin-XX Tyramide Reagent (SKU A8012) offers membrane-impermeant, HRP-mediated signal amplification for low-abundance cell-surface targets in fixed-cell workflows. This scenario-driven guide explains selection, handling, controls, and interpretation for researchers connecting viability or cytotoxicity phenotypes with surface-protein measurements.

• Norovirus Co-opts NINJ1 for Selective NS1 Secretion

  2026-09-03

  Song and colleagues show that murine norovirus repurposes the membrane-rupture factor NINJ1 to release the interferon-antagonistic protein NS1, while still producing broad damage-associated molecular pattern release. The study combines CRISPR screening, caspase-3 perturbation, imaging, protein mutagenesis, and mouse infection models to connect viral protein secretion with enteric pathogenesis.

• CXCR4–EGFR Heteromers Rewire Cancer Signaling

  2026-09-02

  Comez et al. show that CXCR4 and EGFR assemble into ligand-responsive oligomeric signaling complexes rather than functioning only as independent receptors. NanoBRET, nanobody-based proximity ligation assays, and functional coupling measurements link these complexes to PLCγ, Gi proteins, and β-arrestin-2, with endogenous receptor proximity confirmed in HeLa cells.

• Gefitinib (ZD1839) for Cancer Assembloid Studies

  2026-09-02

  Use Gefitinib (ZD1839) as a mechanistic EGFR probe in matched tumor organoids and stromal-integrated assembloids, not only in conventional monolayers. This workflow helps distinguish direct tumor-cell sensitivity from microenvironment-driven resistance while connecting phospho-signaling data to viability, cell-cycle, and apoptosis outcomes.

• Tunicamycin and the UPR: Calibrating ER Stress

  2026-09-01

  Tunicamycin is a powerful N-glycosylation inhibitor for dissecting adaptive versus damaging ER stress. This article translates new C. elegans cadmium-resistance findings into practical assay logic without treating UPR activation as a simple on-or-off endpoint.

• Estradiol Workflows for Receptor–Autophagy Studies

  2026-09-01

  Build reproducible Estradiol assays that separate ERα and ERβ activity from vehicle effects, exposure artifacts, and autophagy-specific changes. This workflow translates multi-organ aging evidence into practical cell-based, pathway, and validation experiments.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-31

  Song et al. show that murine norovirus exploits the host membrane-rupture protein NINJ1 to release the viral immune-modulatory protein NS1 through a caspase-3-dependent unconventional secretion route. The study combines CRISPR screening, imaging, protein mutagenesis, and mouse infection experiments to distinguish selective viral cargo release from the broader damage-associated molecular pattern release associated with cell death.

• Toremifene Workflows for Prostate Cancer Research

  2026-08-31

  Build reproducible Toremifene dose–response, calcium-signaling, and invasion assays for hormone-responsive cancer research. This workflow separates established product specifications from testable hypotheses involving the TSPAN18–STIM1 axis, helping researchers avoid overinterpreting pharmacological effects.

• JNJ-26854165 (Serdemetan) in Cancer Research

  2026-08-30

  JNJ-26854165, also called Serdemetan, is a small-molecule HDM2 antagonist that increases p53 pathway activity by limiting HDM2-mediated protein degradation. Product-reported benchmarks support its use as an anti-proliferative agent, apoptosis inducer, and radiosensitizer in tumor xenografts, while orthogonal assay design is needed to distinguish growth arrest from cell death.

• Isoproterenol Sulfate Dihydrate: Assay Logic

  2026-08-29

  Isoproterenol sulfate dihydrate provides a defined beta-adrenergic challenge for human pacemaker and neuro-cardiac models. This article shows how to use it as a mechanistic assay layer alongside SAN–cardiac plexus assembloids rather than treating beta stimulation as a substitute for innervation.

• SR-202: PPARγ Antagonist Workflow Guide

  2026-08-28

  SR-202 gives researchers a selective way to test whether PPARγ activity drives adipocyte differentiation, insulin resistance, or macrophage-state changes. This workflow guide connects nuclear-receptor pharmacology with obesity research and the PPARγ/STAT pathway while emphasizing controls, solvent handling, and interpretation limits.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-08-28

  BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence, cell death, and cancer-cell growth. This workflow-oriented guide shows how to build dose-response, chromatin, and phenotype assays while managing the compound’s reported insolubility.

• Gastric Cancer Assembloids Reveal Stromal Drug Effects

  2026-08-27

  A 2025 Cancers study developed patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-associated stromal subpopulations. The model revealed that stromal context alters gene expression and drug sensitivity, creating a more informative platform for resistance studies and personalized targeted therapy research.

• IRG1–Itaconic Acid Control of TBK1 and IFN-I

  2026-08-27

  A 2025 Cell Reports study identifies the IRG1–itaconic acid axis as a metabolic feedback mechanism that restrains TBK1-driven type I interferon responses. By showing that itaconic acid alkylates TBK1 at Cys605 and disrupts dimerization, the authors establish a mechanistic link between immunometabolism and innate antiviral signaling and introduce ITA-5 and ITA-9 as candidate inhibitors for IFN-I-mediated hyperinflammation.

7687 records 1/513 page Next 12345 下5页 Last page